First Bank & Trust Incyte Corp Transaction History

First Bank & Trust

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 12, 2023	SELL	$60.95 - $75.51 $74,419 - $92,197	-1,221 Reduced 27.19%	3,269 $203,000
Q1 2023 Apr 25, 2023	BUY	$70.23 - $86.01 $3,160 - $3,870	45 Added 1.01%	4,490 $324,000
Q4 2022 Jan 27, 2023	SELL	$67.18 - $84.11 $2,754 - $3,448	-41 Reduced 0.91%	4,445 $357,000
Q3 2022 Oct 28, 2022	BUY	$66.18 - $82.86 $3,639 - $4,557	55 Added 1.24%	4,486 $299,000
Q2 2022 Jul 22, 2022	BUY	$66.18 - $83.18 $36,399 - $45,749	550 Added 14.17%	4,431 $337,000
Q1 2022 Apr 29, 2022	BUY	$66.02 - $79.71 $256,223 - $309,354	3,881 New	3,881 $308,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of First Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on First Bank & Trust with notifications on news.